Anti-tumor properties of sub-class of xanthine analogs involve restoration of p53 pathway transcriptome, independent of p53/p73, dependent on ATF3/ATF4 and Noxa in mutated-p53 tumors and the compounds trigger an S-phase checkpoint.
Computational methods reveal how mutations affect the conformational landscape of the kinase domain of EGFR resulting in abnormal signaling and provide a structural framework for ongoing drug discovery efforts on mutant-specific EGFR inhibition.
FLT3-ITD/STAT5A signaling is more sensitive to Dot1L inhibition than the canonical MLL-fusion activated drivers of leukemogenesis, providing a potential therapeutic avenue for one of the most frequent lesions in leukemia.
The E2F/Dp transcription factors, which are key cell cycle regulators, can also mediate the regulation of carbohydrate metabolism in larva by controlling both systemic trehalose homeostasis and fat storage.
Erlotinib-resistant AXL overexpressing cells are present in therapy-naive tumors, and expression of AXL in these cells is regulated through a stochastic mechanism centered on the epigenetic regulation of miR-335.
Cellular acidity, capacity for net acid extrusion, and expression of acid-base transporters in human breast carcinomas independently predict variation in proliferative activity, lymph node metastasis, and patient survival.